Juha P. Rasanen, MD, of Oregon Health & Science University in Portland, and colleagues, have described a blood test that identifies glycoprotein biomarkers in pregnant women during the first trimester of pregnancy, accurately predicting gestational diabetes (GDM) 92% of the time. That suggests that doctors may be able to determine a mother’s risk for this condition as early as her first prenatal visit.
The investigators studied fibronectin glycosylation associated with Sambucus nigra lectin binding (FN-SNA), and found that the mean FN-SNA concentration was greater in participants who later developed GDM than in controls (102+30 mg/L vs 56+15 mg/L; P
<0.0001). At a false-positive rate of 4%, FN-SNA alone detected 84% of first-trimester GDM cases. The detection rate increased to 92% with addition of adiponectin and CRP.